One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasisResults ...

UCB, a global biopharmaceutical company, today announced new data in moderate-to-severe plaque psoriasis (PSO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, March 27–31.

EBGLYSS (lebrikizumab-lbkz) delivered durable skin clearance and relief from persistent itch for up to four years for ...

Telegraph columnist Allison Pearson has launched libel proceedings against Essex Police and Crime Commissioner Roger Hirst, ...

Pearson’s first global brand campaign in five years is designed to illustrate all of its products and services, from K–12 and ...

As cities worldwide accelerate toward electrification and decarbonization, the convergence of distributed energy resources and electric mobility is ...

Frequent travel lifestyle impacts health, productivity, and balance. Learn how professionals manage stress, sleep, and ...

T he recent reimbursement of Bimzelx (bimekizumab) in Ireland represents an important step forward in access to treatment for ...

Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety ...

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety ...

Thousands of Oklahomans evacuated Sunday as wildfires spread across the state, fueled by strong winds and high temps. Here's ...

Abstract: Doubly Fed Induction Generators (DFIGs) have been frequently controlled through Direct Field-Oriented Control (DFOC) in Wind Energy Conversion Systems due to their ability to independently ...